EG-1964

EG-1964 is an investigational drug candidate developed by Edge Therapeutics as a **potential prophylactic treatment in the management of chronic subdural hematoma (cSDH)**, a condition involving bleeding on the surface of the brain, often caused by head injury. EG-1964 is being evaluated specifically to prevent recurrent bleeding in cSDH patients. As of the latest available information, EG-1964 remains at early preclinical or pre-Phase 1 development, with clinical development and production still "very far off." The precise mechanism of action, formulation, and detailed pharmacology of EG-1964 have not been publicly disclosed, but it is expected to be related to neurological protection or prevention of rebleeding in subdural hematomas[1][2][3].